Therefore, we tentatively conclude that cMDA may be better or at least comparable to ESR, CRP, and BVAS in predicting all-cause mortality during follow-up in patients with AAV. This evidence concerns the gene CRP and anti-neutrophil cytoplasmic antibody-associated vasculitis.